

1 **The genetic architecture of pain intensity in a sample of 598,339 U.S. veterans**

2 Sylvanus Toikumo^{1,2}, Rachel Vickers-Smith^{1,3}, Zeal Jinwala², Heng Xu², Divya Saini², Emily Hartwell^{1,2},
3 Mirko P. Venegas⁴, Kyle A. Sullivan⁴, Ke Xu^{5,6}, Daniel A. Jacobson⁴, Joel Gelernter^{5,6}, Christopher T.
4 Rentsch^{5,6,7}, Million Veteran Program, Eli Stahl,⁸ Martin Cheattle², Hang Zhou^{5,6}, Stephen G. Waxman^{5,6},
5 Amy C. Justice^{5,6,9}, Rachel L. Kember^{1,2}, Henry R. Kranzler^{1,2}

6
7 ¹Mental Illness Research, Education and Clinical Center, Crescenz VAMC, Philadelphia, PA, USA;
8 ²Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA,
9 USA; ³Department of Epidemiology, University of Kentucky College of Public Health; Center on Drug and
10 Alcohol Research, University of Kentucky College of Medicine, Lexington, KY, USA; ⁴Biosciences Division,
11 Oak Ridge National Laboratory, Oak Ridge, TN, USA; ⁵Veterans Affairs Connecticut Healthcare System,
12 West Haven, CT, USA; ⁶Yale University School of Medicine, New Haven, CT, USA; ⁷London School of
13 Hygiene & Tropical Medicine, London, UK; ⁸Regeneron Genetics Center, Tarrytown, NY, USA; ⁹Yale
14 University School of Public Health, New Haven, CT, USA

15
16 **Corresponding author:** Henry R. Kranzler, MD, Department of Psychiatry, University of Pennsylvania
17 Perelman School of Medicine, Philadelphia, PA, USA. Email: kranzler@pennmedicine.upenn.edu

18
19
20
21
22
23
24
25
26 **Abstract**

27 Chronic pain is a common problem, with more than one-fifth of adult Americans reporting pain daily or
28 on most days. It adversely affects quality of life and imposes substantial personal and economic costs.
29 Efforts to treat chronic pain using opioids played a central role in precipitating the opioid crisis. Despite
30 an estimated heritability of 25-50%, the genetic architecture of chronic pain is not well characterized, in
31 part because studies have largely been limited to samples of European ancestry. To help address this
32 knowledge gap, we conducted a cross-ancestry meta-analysis of pain intensity in 598,339 participants in
33 the Million Veteran Program, which identified 125 independent genetic loci, 82 of which are novel. Pain
34 intensity was genetically correlated with other pain phenotypes, level of substance use and substance
35 use disorders, other psychiatric traits, education level, and cognitive traits. Integration of the GWAS
36 findings with functional genomics data shows enrichment for putatively causal genes ($n = 142$) and
37 proteins ($n = 14$) expressed in brain tissues, specifically in GABAergic neurons. Drug repurposing analysis
38 identified anticonvulsants, beta-blockers, and calcium-channel blockers, among other drug groups, as
39 having potential analgesic effects. Our results provide insights into key molecular contributors to the
40 experience of pain and highlight attractive drug targets.

41

42

43

44

45

46

47

48

49

50

51

52

53 **Introduction**

54 Pain is an unpleasant sensory and emotional experience associated with, or resembling that
55 associated with, actual or potential tissue damage¹. Pain is often classified as either acute, which
56 typically lasts less than 4 weeks, and chronic, lasting more than three months and potentially
57 maladaptive². An individual's experience of pain is influenced by biological, psychological, and social
58 factors^{1,3}.

59 In a national survey, 50.2 million US adults (20.5%) reported experiencing pain on most days or
60 every day⁴, making pain the most common reason for seeking medical treatment⁵ and resulting in total
61 healthcare costs of 560 to 635 billion dollars in 2010⁶. Chronic pain is also associated with a poor quality
62 of life⁷. In the late 1980's many medical and pain organizations adopted policies to increase patients'
63 access to pain management, including opioids. These policies included efforts to ensure the adequate
64 assessment of pain, which was designated as "the fifth vital sign"². The resulting dramatic increase in
65 prescriptions for opioid analgesics contributed to the opioid epidemic and a doubling of opioid-related
66 deaths in the 1990s^{8,9}.

67 Success rates for treating chronic pain with currently available medications are estimated to be
68 as low as 10%¹⁰. Opioids are not efficacious in managing chronic non-cancer pain¹¹ and their long-term
69 use is associated with adverse effects such as addiction, sleep disturbance, opioid-induced hyperalgesia,
70 endocrine changes, and cardiac and cognitive effects^{12,13}. Other medications used to treat chronic non-
71 cancer pain, such as non-steroidal anti-inflammatory medications and antiepileptic drugs, are effective
72 for only some types of pain and may be associated with significant adverse effects¹⁴. Because non-
73 pharmacologic interventions are not accessible to most patients with pain, safe and efficacious
74 medications are needed to address this highly prevalent condition. Thus, novel therapeutic targets for
75 chronic pain are needed to facilitate the discovery or repurposing of safe, effective analgesics.

76 Notably, drug development efforts informed by genetics can double the rate of success¹⁵⁻¹⁷.
77 Although the heritability (h^2) of individual differences in the susceptibility to develop chronic pain is
78 estimated in twin and family studies to be 25–50%^{18,19}, the mechanisms that underlie it are poorly
79 understood²⁰. To date, genome-wide association studies (GWAS) of chronic pain in large samples,
80 including the UK Biobank (UKBB) and 23andMe cohorts, have focused on specific bodily sites²¹⁻²⁴ or
81 aspects of an individual's sensitivity to experiencing and reporting pain²⁵⁻²⁸. Although in samples of
82 150,000 to nearly 500,000 individuals GWAS have identified genome-wide significant (GWS) loci for
83 headache²⁹, osteoarthritis^{30,31}, low back pain^{23,24}, knee pain²¹, neuropathic pain³², and multisite chronic
84 pain^{25,26}, they have yielded few overlapping loci. This may be due to the different pain phenotypes
85 employed, despite their having high genetic correlations among them^{27,33}.

86 There are also significant genetic correlations between pain phenotypes and psychiatric,
87 substance use, cognitive, anthropometric, and circadian traits^{21,23–25,29,34}. This shared genetic
88 predisposition suggests that a common genetic susceptibility underlies a broad range of diverse chronic
89 pain conditions³⁴ and common co-occurring conditions. For example, Mendelian randomization (MR)
90 and latent causal variable analyses have shown positive causal effects of specific bodily site pain on
91 depression^{35,36} and bi-directional casual associations between multisite chronic pain and major
92 depressive disorder (MDD)^{25,35}.

93 Despite a growing literature on pain GWAS, most studies have been conducted in predominantly
94 European ancestry cohorts recruited from non-clinical biobanks. However, biobanks linked to electronic
95 health records (EHRs) with large, well-characterized, multi-ancestry samples are now available for use in
96 identifying genetic risk factors and therapeutic targets for chronic pain³⁷. The Million Veteran Program
97 (MVP)³⁸, an observational cohort study and mega-biobank implemented in the U.S. Department of
98 Veterans Affairs (VA) health care system, includes data on routine pain screening. Pain ratings in the
99 MVP use an 11-point ordinal Numeric Rating Scale (NRS), which has been a standard practice in VA
100 primary care for more than a decade³⁹. The NRS has been shown to be a consistent, valid measure of
101 reported pain^{40–42} and is particularly informative for a GWAS of pain, as over 50% of VA patients
102 experience chronic pain⁴³.

103 We conducted a cross-ancestry meta-analysis of the NRS in samples of African American (AA),
104 European American (EA) and Hispanic American (HA) ancestries from the MVP (N = 598,339). Because of
105 the frequency with which the NRS is administered to patients in the VA, for each individual we
106 calculated the median annual score and then the median across years. Thus, although the NRS is a
107 report of pain intensity experienced at a specific point in time, the median of medians provided a proxy
108 for chronic pain. We also conducted a secondary analysis in a subsample of 566,959 individuals that
109 excluded participants with a lifetime opioid use disorder (OUD) diagnosis to assess potential
110 confounding by OUD.

111

112 **Methods**

113 **Overview of analyses**

114 We conducted ancestry-specific GWASs of pain scores using an 11-point ordinal NRS in a) all
115 AAs, EAs, and HAs with pain ratings from the MVP and b) a subset of these participants that excluded
116 those with a lifetime OUD diagnosis, each followed by a cross-ancestry meta-analysis. Details on

117 phenotyping are provided below. Downstream analyses are based principally on the GWAS of pain
118 scores in the full sample, complemented by the estimated heritability and genetic correlations (r_g s) for
119 the sample exclusive of participants with OUD. An overview of the analyses is provided in
120 Supplementary Fig. 1.

121 **Million Veteran Program cohort**

122 The MVP³⁸ is an EHR-based cohort comprising >900,000 veterans recruited at 63 VA medical
123 centers nationwide. All participants provided written informed consent, a blood sample for DNA
124 extraction and genotyping, and approval to securely access their EHR for research purposes. The
125 protocol and consent were approved by the Central Veterans Affairs Institutional Review Board (IRB)
126 and all site-specific IRBs. All relevant guidelines for work with human participants were followed in the
127 conduct of the study.

128

129 **Phenotype description**

130 As early as 2000, the VA recommended using the NRS to routinely measure pain in clinical
131 practice as a “fifth vital sign”⁴⁴. Since that time, veterans have been asked to rate their pain severity in
132 response to the question: “Are you in pain?” They then rated their current pain on a scale of 0-10 where
133 “0 is no pain and 10 is the worst pain imaginable”. Participants had at least one inpatient or outpatient
134 pain rating in the EHR. We included 598,339 individuals with 76,798,104 NRS scores (median number of
135 scores = 109, IQR = 28 – 351) in the primary GWAS. To reduce the large number of pain observations, we
136 calculated the median pain score by year for each participant and the median of the annual median pain
137 scores. In a supplementary GWAS we excluded individuals with a documented ICD-9/10 diagnosis code
138 for OUD in the EHR, yielding a total of 566,959 study participants. Demographic characteristics for the
139 supplementary sample are presented in Supplementary Table 1.

140

141 **Genotyping and imputation**

142 DNA samples were genotyped on the Affymetrix Axiom Biobank Array (MVP Release 4). For
143 genotyped SNPs, standard quality control (QC) and subsequent imputation were implemented. Full
144 details about SNP and sample QC by the MVP Genomics Working Group are published⁴⁵. Briefly, DNA
145 samples were removed for sex mismatch, having seven or more relatives in MVP (kinship > 0.08),
146 excessive heterozygosity, or genotype call rate < 98.5%. Variants were removed if they were
147 monomorphic, had a high degree of missingness (call rate < 0.8) or a Hardy–Weinberg equilibrium

148 (HWE) threshold of $P < 1 \times 10^{-6}$ both in the entire sample using a principal-component analysis (PCA)-
149 adjusted method and within one of the three major ancestral groups (AA, EA and HA).

150 Genotype phasing and imputation were performed using SHAPEIT4 (v.4.1.3)⁴⁶ and Minimac4
151 software⁴⁷, respectively. Biallelic SNPs were imputed using the African Genome Resources reference
152 panel by the Sanger Institute (comprising all samples from the 1000 Genomes Project phase 3, version 5
153 reference panel⁴⁸, and 1,500 unrelated pan-African samples). Non-biallelic SNPs and indels were
154 imputed in a secondary imputation step using the 1000 Genomes Project phase 3, version 5 reference
155 panel⁴⁸, with indels and complex variants from the second imputation merged into the African Genome
156 Resources imputation.

157 We removed one individual from each pair of related individuals (kinship > 0.08 , $M = 31,010$)
158 at random. The HARE method⁴⁹ was used to classify subjects into major ancestral groups (AA = 112,968,
159 EA = 436,683, HA = 48,688) and QC of imputed variants was performed within each ancestral group.
160 SNPs with imputation quality (INFO) score < 0.7 ; minor allele frequency (MAF) in AAs < 0.005 ,
161 EAs < 0.001 , and HAs < 0.01 ; a genotype call rate < 0.95 ; or an HWE $P < 1 \times 10^{-6}$ were excluded.

162 **Association analyses and risk locus definition**

163 Genome-wide association testing was based on a linear regression model using PLINK (v.2.0)⁵⁰
164 and was adjusted for sex, age at enrollment, and the first 10 within-ancestry genetic principal
165 components (PCs). Due to substantial differences in sample size across ancestral groups, meta-analyses
166 were performed using a sample-size weighted method in METAL⁵¹. Variants with $P < 5 \times 10^{-8}$ were
167 considered genome-wide significant (GWS).

168 To identify risk loci and their lead variants, we performed LD clumping in FUMA⁵² at a range of
169 3,000 kb, $r^2 > 0.1$, and the respective ancestry 1000 Genomes reference panel⁴⁸. Following clumping,
170 genomic risk loci within 1 Mb of one another were incorporated into the same locus. We used GCTA
171 COJO⁵³ to define independent variants by conditioning them on the most significant variant within the
172 locus. After conditioning, significant variants ($P < 5 \times 10^{-8}$) were considered independently associated.
173 We performed a sign test to compare the direction of SNP effects across individual ancestral datasets.
174 Independent lead variants in EAs were examined in AAs and HAs and a binomial test used to evaluate
175 the null hypothesis that 50% of variants have the same effect direction across ancestries. For lead SNPs

176 in EAs that were absent in AAs and HAs, we considered proxy GWS SNPs ($p < 5 \times 10^{-8}$) in high LD with the
177 EA lead variant ($r^2 \geq 0.8$).

178 To prioritize credible sets of variants driving our GWAS results, we used FINEMAP⁵⁴ to fine-map
179 regions defined by LD clumps ($r^2 > 0.1$). Because fine-mapping requires data from all markers in the
180 region of interest⁵⁵, we merged LD clumps that physically overlapped (within a 1-MB window of the lead
181 variant) and excluded SNPs in the major histocompatibility complex (MHC) region due to its complexity.
182 FINEMAP credible set reports the likelihood of causality using the marginal posterior probability (PP),
183 which ranges from 0 to 1, with values closer to 1 being most likely causal.

184 **SNP-based heritability and functional enrichment**

185 We used the linkage disequilibrium score (LDSC) regression⁵⁶ method to estimate the SNP-based
186 heritability (h^2_{SNP}) of pain intensity (in both the full and the supplementary samples) in AAs and EAs
187 based on common SNPs in HapMap3⁵⁷. Due to the small HA sample size, we could not calculate h^2_{SNP} in
188 this population. To ensure matching of population LD structure, pre-calculated LD scores for EAs were
189 derived from the 1000 Genomes European reference population (version 3)⁴⁹ using LDSC⁵⁶. In-sample LD
190 scores for AAs were calculated from MVP AA genotype data using cov-LDSC⁵⁸.

191 We used S-LDSC to partition the SNP heritability for pain intensity among EAs and explored the
192 enrichment of the partitioned heritability by functional genomic categories^{59,60} using three models: (a) a
193 baseline-LD model that contains 75 overlapping annotations, including coding and regulatory regions of
194 the genome and epigenomic features⁵⁹ (b) a specific tissue model that examines 10 overlapping cell-
195 type groups derived from 220 cell-type-specific histone marks, including methylated histone H3 Lys4
196 (H3K4me1), trimethylated histone H3 Lys4 (H3K4me3), acetylated histones H3 Lys4 (H3K4ac) and
197 H3K27ac⁵⁹ and (c) a multi-tissue model based on gene expression and chromatin datasets generated by
198 GTEx⁶¹ and the Roadmap Epigenomics Mapping Consortium⁶². For each model, we excluded multi-allelic
199 and MHC region variants. Functional categories within each model were considered significantly
200 enriched based on a Bonferroni-corrected P value.

201 **Gene-set functional characterization**

202 We applied multi-marker analysis of genomic annotation (MAGMA) v.1.08⁶³ in FUMA (v1.3.6a)⁵²
203 to identify genes and gene sets associated with the findings from the pain intensity GWAS and meta-
204 analysis. Using the default setting in MAGMA, we mapped GWS SNPs to 18,702 protein-coding genes

205 according to their physical position in NCBI build 37. We also used chromatin interaction (Hi-C) coupled
206 MAGMA (H-MAGMA)⁶⁴ to assign non-coding (intergenic and intronic) SNPs to genes based on their
207 chromatin interactions. H-MAGMA uses six Hi-C datasets derived from fetal brain, adult brain (N = 3),
208 induced pluripotent stem cell (iPSC)-derived neurons and iPSC-derived astrocytes⁶⁵. We applied a
209 Bonferroni correction (MAGMA, $\alpha = 0.05/18,702$; H-MAGMA, $\alpha = 0.05/293157/6$) to identify genes
210 significantly associated with pain intensity, correcting for all genes tested in each analysis (see
211 Supplementary Tables 15 and 21 for full lists).

212 To determine the plausible tissue enrichment of mapped genes, we integrated our cross-
213 ancestry and EA GWAS results with gene expression data from 54 tissues (GTEx v8) in FUMA⁵². Next, we
214 used FUMA to curate gene sets and Gene Ontology terms (from the Molecular Signature Database
215 v.7.0⁶⁶). We corrected for gene size, density of variants, and LD pattern between genes in each tissue
216 (Bonferroni-corrected $\alpha = 0.05/54$).

217 Enrichment for cell-type specific (CTS) transcriptomic profiles was performed in FUMA⁶⁷ using 13
218 human single-cell RNA-sequencing (sc-RNAseq) datasets derived from brain (see Supplementary Table
219 14 for a detailed list). FUMA estimates CTS transcriptomic enrichment from the sc-RNAseq in three
220 ways: (1) per selected dataset, (2) within datasets using a conditionally independent analysis (based on
221 stepwise conditional testing of P values for each cell type that passes Bonferroni correction within the
222 same dataset), and (3) across datasets (testing for proportional significance across the results from step
223 2). Proportional significance (PS) reports the confidence level for observed cell type enrichment as low
224 significance: < 0.5 , jointly significant: $0.5 - 0.8$; and independently significant: > 0.8 . We considered CTS
225 enrichments with conditional independent signals ($P < 0.05$) and PS > 0.5 to be driven by
226 joint/independent genetic signals in our pain intensity GWAS results.

227 **Transcriptomic and proteomic regulation**

228 To identify genes and proteins whose expression is associated with pain intensity, we integrated
229 EA GWAS results with human brain transcriptomic (eQTL, N = 452; and sQTL, N = 452)^{68,69} and proteomic
230 (N = 722)⁶² data. We also obtained pretrained models of gene expression from GTEx v.8 for five brain
231 tissues significantly enriched in MAGMA analyses – cerebellum, cerebellar hemisphere, cortex, frontal
232 cortex, and anterior cingulate cortex^{61,71}. Human brain transcriptomic and proteomic data for
233 dorsolateral prefrontal cortex were derived from the study by Wingo et al⁷⁰. Transcriptome-wide
234 association study (TWAS) and proteome-wide association study (PWAS) analyses were performed using

235 the FUSION pipeline⁷¹ with Bonferroni correction ($\alpha = 0.05/N$ genes tested) to account for multiple
236 testing.

237 We used the colocalization (coloc R package⁷² in FUSION⁷¹) as our primary method to identify
238 SNPs that mediate association with pain intensity through effects on gene and protein expression and a
239 posterior colocalization probability (PP) of 80% to denote a shared causal signal. To test the robustness
240 of the colocalized signals, we also performed summary-based Mendelian randomization (SMR)
241 analyses⁷³. We applied the HEIDI test⁷³ to filter out SMR signals ($P_{\text{HEIDI}} < 0.05$) due to linkage
242 disequilibrium between pain-associated variants and eQTLs/sQTLs. Human brain cis-eQTL and cis-sQTL
243 summary data were obtained from Qi et al⁷⁴ and GTEx⁶¹. For genomic regions containing multiple genes
244 with significant SMR associations, we selected the top-associated cis-eQTL. We used Bonferroni
245 correction to correct for multiple testing ($\alpha = 0.05/N$ genes tested).

246 To explore the enrichment of causal genes and proteins in the dorsal root ganglia (DRG), we
247 accessed human and mouse RNA-seq data from 13 tissues (6 neural and 7 non-neural) from the DRG
248 sensoryomics repository⁷⁵. The data contain relative gene abundances in standardized transcripts per
249 million mapped reads and have been normalized to allow comparison across genes. The proportions of
250 gene expression in the CNS (neural proportion score) and DRG (DRG enrichment score) in the context of
251 profiled tissues were calculated, as described in Ray et al⁷⁵. Scores ranging from 0 to 1 were used to
252 denote the strength of tissue enrichment.

253 **Drug repurposing**

254 We examined the drug repurposing status of genes in EAs (N = 156) with high causal probability
255 from fine mapping and transcriptomic and proteomic analyses, using the Druggable Genome database⁷⁶.
256 For completeness, we also included the significantly associated genes mapped to GWS variants and
257 MAGMA results in AAs (N = 7) and HAs (N = 2). The Druggable Genome database contains 4,479 coding
258 gene sets with the potential to be modulated by a drug-like small molecule based on their nucleotide
259 sequence and structural similarity to targets of existing drugs⁷⁶. This druggable genome was divided into
260 three tiers. Tier 1 (N = 1,427) contains targets of licensed small molecules and biotherapeutic drugs
261 (curated from the ChEMBL database⁷⁷) and drugs in clinical development. Tier 2 (N = 682) includes
262 targets with verified bioactive drug-like small molecule binding partners and > 50% identity with
263 approved drug targets based on their nucleotide sequence. Tier 3 (N = 2,370) comprises targets or
264 secreted proteins with more distant similarity with an approved drug and members of active protein

265 complexes not included in Tiers 1 and 2. All causal genes and those reported in any of the three tiers of
266 the Druggable Genome were also examined for interaction with prescription drug targets in clinical
267 development using the Drug-Gene Interaction database (DGIdb)⁷⁸, which compiles clinical trial
268 information from the FDA, PharmGKB, Therapeutic Target Database, and DrugBank databases, among
269 others. We categorized each prescription drug identified using the Anatomical Therapeutic Chemical
270 classification system, retrieved from the Kyoto Encyclopedia of Genes and Genomics
271 (<https://www.genome.jp/kegg/drug/>).

272 **Genetic correlation**

273 We used LDSC⁵⁶ to calculate the r_g of pain intensity with (a) 89 other published pain, substance
274 use, medication use, psychiatric, and anthropometric traits from EA datasets selected using prior
275 epidemiological evidence and (b) 12 psychiatric, substance use, and anthropometric traits based on
276 available AA GWAS summary data (see Supplementary Tables 24 and 26 for detailed lists). In EAs, all
277 traits were tested using pre-computed LD scores for HapMap3⁵⁷, while in AAs, LD scores derived using
278 cov-LDSC⁵⁸ from MVP AA genotype data were used. In a hypothesis-neutral manner, we also calculated
279 r_g s of pain intensity with 1344 published and unpublished traits from the UKBB using the Complex Trait
280 Virtual Lab (CTG-VL) (<https://genoma.io/>). CTG-VL is a free open-source platform that incorporates
281 publicly available GWAS data that allow for the calculation of r_g for complex traits using LDSC⁷⁹. Each set
282 of r_g analyses was Bonferroni corrected to control for multiple comparisons ($\alpha = 0.05/\text{number of traits}$
283 tested).

284 We also estimated the cross-ancestry r_g s for pain intensity between AAs, EAs and HAs using
285 Popcorn⁸⁰, a computational method that determines the correlation of causal-variant effect sizes at
286 SNPs common across population groups using GWAS summary-level data and LD information. Ancestry-
287 specific LD scores were derived from the 1000 Genomes reference population⁴⁸.

288 **Polygenic risk score-based phenome-wide association studies**

289 We calculated polygenic risk scores (PRS) for pain intensity and performed a PheWAS analysis in
290 two samples – the Yale-Penn sample and the Penn Medicine Biobank (PMBB). The Yale-Penn sample⁸¹
291 was deeply phenotyped using the Semi-Structured Assessment for Drug Dependence and Alcoholism
292 (SSADDA), a comprehensive psychiatric instrument that assesses physical, psychosocial, and psychiatric
293 aspects of SUDs and comorbid psychiatric traits^{82,83}. As described in detail previously⁸¹, genotyping was
294 performed using the Illumina HumanOmni1-Quad microarray, the Illumina HumanCoreExome array, or

295 the Illumina Multi-Ethnic Global array, followed by imputation using Minimac3⁸⁴ and the 1000 Genomes
296 Project phase3 reference panel⁴⁸ implemented on the Michigan imputation server
297 (<https://imputationserver.sph.umich.edu>). SNPs with imputation quality (INFO) score ≤ 0.7 , MAF <
298 0.01, missingness > 0.01, or an allele frequency difference between batches > 0.04; and individuals with
299 genotype call rate ≤ 0.95 , or related individuals with pi-hat > 0.25 were excluded. PCs were used to
300 determine genetic ancestry based on the 1000 Genomes Project phase3⁴⁸. The resulting dataset
301 included 4,922 AAs and 5,709 EAs.

302 The PMBB⁸⁵ is linked to EHR phenotypes. PMBB samples were genotyped with the GSA
303 genotyping array. Genotype phasing was done using EAGLE⁸⁴ and imputation was performed using
304 Minimac3⁸⁴ on the TOPMed Imputation server⁴⁷. Following QC (INFO < 0.3, missingness > 0.95, MAF > 0.5,
305 sample call rate > 0.9), PLINK 1.90 was used to identify and remove related individuals based on identity
306 by descent (Pi-hat > 0.25). To estimate genetic ancestry, PCs were calculated using SNPs common to the
307 PMBB and the 1000 Genomes Project phase3⁴⁸ and the smartpca module of the Eigensoft package
308 (<https://github.com/DReichLab/EIG>). Participants were assigned to an ancestral group based on the
309 distance of 10 PCs from the 1000 Genomes reference populations. The resulting dataset included 10,383
310 AAs and 29,355 EAs.

311 PRSs for pain intensity were calculated in the Yale-Penn and the PMBB datasets using PRS-
312 Continuous shrinkage software (PRS-CS)⁸⁶, with the default setting used to estimate the shrinkage
313 parameters and the random seed fixed to 1 for reproducibility. To identify associations between the
314 pain intensity PRSs and phenotypes, we performed a PheWAS in each dataset by fitting logistic
315 regression models for binary traits and linear regression models for continuous traits. Analyses were
316 conducted using the PheWAS v0.12 R package⁸⁷ with adjustment for sex, age at enrollment (in PMBB) or
317 at interview (in Yale-Penn) and the first 10 PCs within each genetic ancestry. We Bonferroni corrected
318 each ancestry-specific analysis (Yale-Penn EAs and AAs: $P < 8.10 \times 10^{-5}$, PMBB EAs and AAs: $P < 3.68 \times 10^{-5}$).

320 **Mendelian Randomization**

321 We used two-sample Mendelian randomization⁸⁸ to evaluate causal associations between 16
322 genetically correlated traits and pain intensity among EAs only because the two other population groups
323 provided inadequate statistical power for the analysis. We inferred causality bidirectionally using three
324 methods: weighted median, inverse-variance weighted (IVW) and MR-Egger, followed by a pleiotropy
325 test using the MR Egger intercept. Instrumental variants were associated with the exposure

326 at $P < 1 \times 10^{-5}$ and a clumping threshold of $r^2 = 0.01$. Potential causal effects were those for which at
327 least two MR tests were significant after multiple correction ($P = 3.13 \times 10^{-3}$, 0.05/16) and did not
328 violate the assumption of horizontal pleiotropy (MR-Egger intercept $P > 0.05$).

329 Results

330 Description of the sample

331 The study sample comprised 598,339 individuals (AA = 112,968, EA = 436,683, HA = 48,688), of
332 whom 91.2% were male (Supplementary Table 1). The supplementary analyses from which individuals
333 with a lifetime OUD diagnosis were excluded were reduced by 5% across population groups (AA =
334 104,050, EA = 415,740, HA = 46,169) (Supplementary Table 1). The median ages were 61.4 (s.d = 14.0)
335 and 61.7 (s.d = 14.1) in the full and supplementary samples, respectively. About half of individuals in
336 both the full sample (51.2%) and the supplementary sample (52.7%) reported a median NRS of 0, i.e., no
337 pain. Mild (NRS 1-3), moderate (NRS 4-6) and severe pain (NRS 7-10) were reported by 24.4%, 19.2%,
338 and 4.5%, respectively in the full sample, and 24.6%, 18.2%, and 4.0%, respectively in the supplementary
339 sample.

340 Identification of pain intensity risk loci

341 In our cross-ancestry meta-analysis of AA, EA, and HA samples, we identified 4,416 GWS variants
342 represented by 158 LD-clumped index variants ($r^2 > 0.1$) (Figure 1). Analyses conditioned on the lead
343 SNP left 125 independent association signals (Supplementary Table 2), 42 of which have previously been
344 reported as pain-related loci^{23,25} and 82 of which are novel (Supplementary Table 2). Eight independent
345 variants are exonic, 84 reside within a gene transcript, and 33 are intergenic. Of the 8 exonic variants, 2
346 have likely damaging (PolyPhen > 0.5, CADD > 15) effects (*SLC39A8*-rs13107325 and *WSCD2*-rs3764002)
347 and 5 are potentially deleterious (CADD > 15; *ANAPC4*-rs34811474, *MIER*-rs2034244, *NUCB2*-rs757081,
348 *AKAP10*-rs203462 and *APOE*-rs429358) (Supplementary Table 2). The GWAS in EAs yielded 103 LD
349 clumps ($r^2 > 0.1$) across 86 independent loci (Supplementary Figure 2, Supplementary Table 3). Of these,
350 15 were not GWS in the cross-ancestry meta-analysis (Supplementary Table 3). We also identified 2
351 GWS variants in 1 locus (nearest gene *PPARD*; chr 6) in AAs, and 15 GWS variants in 2 loci (nearest genes
352 *RNU6-461P*; chr 3 and *RNU6-741P*; chr 15) in HAs (Supplementary Table 4).

353 [Insert Figure 1 here]

354 We used a sign test to examine the 86 independent EA index variants in AAs and HAs, of which
355 57 and 74, respectively, were directly analyzed or had proxy SNPs in these populations (Supplementary
356 Table 5). Most variants had the same direction of effect in both populations (N_{SNPs} AAs = 41, HAs = 61;
357 sign test AAs $P = 0.0013$, HAs $P = 1.39 \times 10^{-8}$). Only 15 variants (N_{SNPs} AAs = 2, HAs = 13) were nominally
358 associated ($P < 0.05$) and none survived multiple test correction (Supplementary Table 5). The cross-
359 ancestry genetic-effect correlation (ρ_{pe}) was 0.71 (SE = 0.13, $P = 2.12 \times 10^{-2}$) between EAs and AAs and
360 0.74 (SE = 0.08, $P = 6.81 \times 10^{-4}$) between EAs and HAs. The cross-ancestry heritability estimates between
361 AAs and HAs were too low to calculate ρ_{pe} between those ancestries.

362 In the supplementary analysis that excluded participants with a lifetime OUD diagnosis, we
363 identified 3,400 SNPs in 101 LD-independent risk loci (Supplementary Table 6). Of these, 87 were GWS,
364 13 were $p < 10^{-6}$ in the primary GWAS, and 18 were ancestry specific (17 in EAs and 1 in AAs)
365 (Supplementary Tables 7 & 8).

366 **Single-nucleotide polymorphism heritability and enrichment**

367 The proportion of variation in pain intensity explained by common genetic variants (h^2_{SNP}) was
368 similar both for the full samples (AAs: 0.06 ± 0.009 and EAs: 0.08 ± 0.003) and the supplementary
369 samples without OUD (AAs: 0.07 ± 0.009 and EAs: 0.08 ± 0.003) (Supplementary Table 9).

370 Partitioning the SNP heritability for pain intensity revealed significant tissue-group enrichment
371 in central nervous system (CNS) ($P = 1.47 \times 10^{-12}$), adrenal ($P = 8.97 \times 10^{-5}$), liver
372 ($P = 3.15 \times 10^{-4}$), skeletal ($P = 8.50 \times 10^{-4}$) and cardiovascular ($P = 0.001$) tissues (Figure 2A & B,
373 Supplementary Table 10). In gene expression datasets derived from multiple tissues, we observed
374 predominant h^2_{SNP} effects in brain ($P = 2.87 \times 10^{-5}$), including hippocampus ($P = 1.00 \times 10^{-4}$) and
375 limbic system ($P = 1.15 \times 10^{-4}$) (Figures 2C & D, Supplementary Table 11). SNP-based heritability in
376 histone modification data also showed robust enhancer (H3K27ac and H3K4me1) and active promoter
377 (H3K4me3 and H3K9ac) enrichments in brain tissues, including the dorsolateral prefrontal cortex
378 ($P < 1.32 \times 10^{-4}$), inferior temporal lobe ($P < 3.09 \times 10^{-4}$), angular gyrus ($P = 8.42 \times 10^{-5}$), and
379 anterior caudate ($P = 1.12 \times 10^{-4}$) (Figure 2E, Supplementary Table 12). Similar results were obtained
380 for the partitioned heritability analysis of the supplementary GWAS (Supplementary Tables 11 & 12),
381 though it also included significant expression effects in the cortex and cerebellum.

382 Although the SNP-based heritability and enrichment for the full and supplementary GWASs
383 were similar, because the full sample yielded more risk loci, we based all downstream analyses (except
384 genetic correlation [r_g] analyses) on the GWAS results from that sample.

385 [Insert Figure 2 here]

386 Gene-set enrichment in tissue and cell types

387 To clarify the potential transcriptomic mechanism of each GWS pain locus, we mapped GWAS
388 variants to genes via expression quantitative trait locus (eQTL) association in GTEx⁶¹ and assessed the
389 tissue enrichment of mapped genes in FUMA⁵². After correcting for multiple testing ($P_{\text{adj}}=9.25 \times 10^{-4}$)
390 in the cross-ancestry and EA-specific GWASs, we uncovered significant transcriptomic enrichment only
391 in brain tissues (Supplementary Figure 3). Consistent with previous findings of brain tissue enrichment
392 across different pain phenotypes in EAs^{22,25,27}, both our EA and cross-ancestry analyses showed notable
393 enrichment in the cerebellum (cross-ancestry, $P_{\text{adj}}=2.48 \times 10^{-7}$; EA, $P_{\text{adj}}=2.90 \times 10^{-6}$), cerebellar
394 hemisphere (cross-ancestry, $P_{\text{adj}}=4 \times 10^{-7}$; EA, $P_{\text{adj}}=6.23 \times 10^{-6}$), cortex (cross-ancestry,
395 $P_{\text{adj}}=2.79 \times 10^{-6}$; EA, $P_{\text{adj}}=33 \times 10^{-4}$), and frontal cortex (cross-ancestry, $P_{\text{adj}}=2.82 \times 10^{-6}$; EA,
396 $P_{\text{adj}}=4.17 \times 10^{-4}$) (Supplementary Figure 3). Among AAs there were no significantly enriched tissues
397 (Supplementary Table 13).

398 To investigate enrichment at the level of the cell type in the EA GWAS results, we conducted
399 FUMA cell-type specific analysis⁶⁷ in a collection of cell types in 13 human brain sc-RNAseq datasets.
400 After adjusting for possible confounding due to correlated expression within datasets using a stepwise
401 conditional analysis, we detected jointly significant cell-type enrichments (proportional significance, $PS >$
402 0.5) for GABAergic neurons largely in the human adult mid-brain ($P_{\text{adj}}=0.003$, $\beta = 0.206$, s.e. = 0.075, PS
403 0.56) and to a lesser extent in the prefrontal cortex ($P_{\text{adj}}=0.044$, $\beta = 0.045$, s.e. = 0.016, PS 0.39)
404 (Supplementary Table 14).

405 Prioritization of candidate genes

406 To facilitate the biological interpretation and identification of druggable targets, we used a
407 combination of MAGMA and fine-mapping, transcriptomic, proteomic, and chromatin interaction
408 models to prioritize high-confidence variants and genes that most likely drive GWAS associations.
409 Assigning SNPs to genes using physical proximity, MAGMA gene-based analyses⁶³ identified 6 GWS
410 genes in AAs, 203 in EAs, and 125 in the cross-ancestry results (Supplementary Figure 4, Supplementary
411 Table 15), but none in HAs. MAGMA gene-set analysis⁶³ using cross-ancestry GWAS results identified

412 significantly enriched biological processes in catecholamine uptake (GO:0051944; Bonferroni $P=0.019$)
413 and startle response (GO:0001964; Bonferroni $P=0.024$). Negative regulation of synaptic transmission
414 (GO:0050805; Bonferroni $P=0.016$) was related to pain intensity in EAs (Supplementary Table 16).

415 For consistency with available reference data, we based the fine mapping procedure on EA
416 GWAS results using 78 genomic regions (spanning 103 index variants) (Supplementary Table 17) defined
417 by the maximum physical distance between the LD block of independent lead SNPs (Methods).
418 Functional genomic prediction models used the full EA GWAS results (Supplementary Figure 1).

419 We fine-mapped the 78 regions using the Bayesian method implemented in FINEMAP⁵⁴
420 (Methods). For each region with independent causal signals (Supplementary Table 17), credible sets of
421 variants ($PP > 0.5$) were constructed to capture 95% of the regional posterior probability ($k \leq 5$,
422 Supplementary Table 18). Of these regions, 4 harbored 1 SNP (potentially indicating the causal variant),
423 20 regions 2 SNPs and 44 regions 3 or more SNPs (Supplementary Table 18). In total, FINEMAP
424 prioritized 76 unique credible variants ($N = 108$, Figure 3A), including 26 independent lead SNPs and 18
425 novel pain loci (Figure 3B). Most (50/76) of the credible variants map to protein-coding genes and are
426 mostly eQTLs (Supplementary Table 18), and five harbor missense variants, of which three (*ANAPC4*,
427 *APOE*, and *SLC39A8*) are known pain loci^{25,31} and two (*RYR2* and *AKAP10*) are novel (Figure 3B). This
428 small proportion of missense variants and high eQTL enrichment are consistent with an increased
429 probability that the credible variants influence liability to pain intensity through gene expression
430 modulation.

431 We performed TWAS and PWAS analyses to determine whether risk variants exert their effects
432 via gene and/or protein expression. After correction for multiple testing, 196 unique genes (TWAS eQTL
433 – 294, TWAS sQTL – 67 and PWAS – 32) were associated with pain intensity (Supplementary Tables 19 &
434 20). Of these, 69 represent novel associations (based on a window from the index GWAS locus > 1 MB).
435 PWAS showed significant associations in the dorsolateral prefrontal cortex (dlPFC) that overlapped for
436 22 unique genes across multiple brain tissues in the TWAS (eQTL – 16, sQTL – 8) (Figure 3C).

437 [Insert Figure 3 here]

438 Chromatin interaction mapping using Hi-C data in adult and fetal brain identified 512 unique
439 significantly interacting genes ($P=2.84 \times 10^{-8}$) (Supplementary Table 21), of which 60 are associated
440 with all six chromatin annotations (Supplementary Figure 5) and 20 overlap with TWAS and/or PWAS

441 findings, including *DPYSL5*, *KHK*, *MAPRE3*, *MST1R*, *NEK4*, *GNL3*, *GRK4*, *UHRF1BP1* and *VKORC1* (Figure
442 3C, Supplementary Tables 19, 20 & 21).

443 Based on concordant evidence from colocalization analyses in TWAS and PWAS (COLOC PP4 >
444 0.80), 104 unique genes (TWAS eQTL – 139, TWAS sQTL – 20 and PWAS – 14) were putatively causal for
445 pain intensity (Supplementary Tables 19 & 20), of which 10 (including *DPYSL5*, *GRK4*, *KHK* and *MST1R*)
446 were validated by SMR analysis ($P_{\text{HEIDI}} > 0.05$) (Figure 3D, Supplementary Table 22). Among the 104
447 genes, 6 (*CHMP1A*, *GRIA1*, *GRK4*, *MST1R*, *STMN3* and *TRAF3*) captured 50% or more of the FINEMAP
448 posterior probability (Supplementary Table 18). Notably, the *MST1R* intronic locus (rs9815930), which is
449 in a credible set that harbors four other variants in high LD with the novel index variant rs2247036
450 (nearest gene – *TRAIIP*) (Supplementary Figure 6), displayed the most robust causal effects from COLOC
451 and SMR in more than one brain tissue (Figure 3D).

452 We also explored enrichment of causal genes and proteins in the dorsal root ganglia (DRG),
453 which are important for transduction of nociceptive signals from the periphery to the CNS. None of the
454 causal genes or proteins (N = 104) were enriched in human or mouse DRG (DRG enrichment score > 0.5)
455 (Supplementary Figure 7A). Supporting results from TWAS and PWAS, 63 unique genes (human – 38 and
456 mouse – 49) were primarily enriched in the CNS, of which 22 (including *GRK4*, *GRIA1*, *MAPRE3*, *NEK4*,
457 *STMN3* and *TRAF3*) showed common enrichment patterns across species (Supplementary Figure 7B).

458 Integrating FINEMAP, colocalization and SMR prioritized 156 high-confidence genes underlying
459 the pain intensity GWAS association, of which 5 are exonic and missense (Supplementary Table 23), and
460 151 exert their effect via gene or protein expression.

461 **Phenotypic correlates of pain intensity**

462 As expected, the strongest positive genetic correlations of pain intensity were with other pain
463 phenotypes (e.g., multisite chronic pain $r_g=0.789$, osteoarthritis $r_g=0.710$, neck/shoulder pain $r_g=0.669$,
464 back pain $r_g=0.697$, hip pain $r_g=0.729$, knee pain $r_g=0.637$; Figure 4A). Of 72 medical, anthropometric, or
465 psychiatric traits associated epidemiologically with pain severity and mortality, 56 were significantly
466 genetically correlated with pain intensity in EAs (Bonferroni $P < 5.62 \times 10^{-4}$) (Figure 4A, Supplementary
467 Table 24).

468 [Insert Figure 4 here]

469 Notably, the liability to pain intensity was significantly positively genetically correlated with
470 neuroticism, depression, insomnia, a variety of smoking-related measures, cannabis use disorder (CUD),
471 alcohol dependence, OUD, and overweight and obesity (Figure 4A). As in prior studies^{24,29,89}, pain
472 intensity was significantly negatively correlated with educational attainment, cognitive performance,
473 intelligence, and age of smoking initiation (Figure 4A). Relevant to drug repurposing, pain intensity was
474 also positively correlated with the use of a variety of analgesic and anti-inflammatory drugs (Figure 4A).
475 We also found significant r_g s with pain intensity for several medical conditions and health outcomes in
476 the UKBB (including genitourinary disease, chronic bronchitis, angina, etc., Bonferroni $P < 3.72 \times 10^{-5}$,
477 Supplementary Table 25). In AAs, pain intensity was positively genetically correlated with PTSD-related
478 features (e.g., re-experiencing, hyperarousal) and nominally associated ($p < 0.05$) with substance use
479 traits (e.g., maximum alcohol intake and smoking trajectory, Supplementary Table 26).

480 In the Yale-Penn sample, we calculated PRS for 4,922 AAs and 5,709 EAs. Among AAs, none of
481 the associations survived Bonferroni correction, likely due to the smaller discovery sample than for EAs
482 (Supplementary Figure 8, Supplementary Table 27). In EAs, PheWAS identified 147 phenotypes,
483 including 107 in the substance-related domain (40 opioid-related, 30 cocaine-related, 20 tobacco-
484 related, 12 alcohol-related, and 6 cannabis-related) and 39 in other domains (9 medical, 18 psychiatric
485 [9 PTSD, 5 ADHD, 2 conduct disorder, and 2 antisocial], 7 early childhood environmental, and 5
486 demographic phenotypes) that were significantly associated with the pain PRS (Supplementary Figure 9,
487 Supplementary Table 27). The most significant findings were a negative association of the pain severity
488 PRS with educational attainment ($P = 2.39 \times 10^{-26}$) and a positive association with the Fagerström Test
489 for Nicotine Dependence ($P = 4.71 \times 10^{-25}$). Opioid dependence was also positively associated with the
490 pain PRS ($P = 3.87 \times 10^{-12}$), and remained significant when using a PRS based on the supplementary
491 GWAS that excluded individuals with an OUD diagnosis (OR = 1.27, $P = 1.35 \times 10^{-6}$).

492 In PMBB, we calculated PRS for 10,383 AAs and 29,355 EAs. In AAs, no association with the pain
493 PRS survived Bonferroni correction (Supplementary Figure 10, Supplementary Table 28). In EAs, the pain
494 severity PRS was associated with 63 phenotypes, including 7 pain phenotypes and 6 psychiatric
495 disorders (i.e., substance-, depression-, and anxiety-related traits). Other phenotypic categories with
496 associations with the pain severity PRS were circulatory system (n=11), infectious diseases (n=4),
497 endocrine/metabolic (n=8), genitourinary (n=2), musculoskeletal (n=3), and neoplasms (n=4). The most
498 significant findings were positive correlations with obesity ($P = 1.97 \times 10^{-45}$) and tobacco use disorder

499 ($P=1.55 \times 10^{-24}$) and a negative association with benign neoplasm of skin ($P=2.67 \times 10^{-26}$)
500 (Supplementary Figure 11, Supplementary Table 28).

501 Two-sample MR between genetically correlated traits ($N = 16$) and pain intensity yielded 10
502 traits with evidence of causal association, 8 of which were bidirectional (Supplementary Table 29).
503 Genetically predicted higher opioid use (N02A), depressed affect subcluster, major depressive disorder,
504 neuroticism, use of drugs to treat peptic ulcer, and smoking cessation (coded as current smoking) had a
505 significant positive bidirectional causal effect with pain intensity, whereas educational attainment and
506 cognitive performance had a significant negative bidirectional causal effect (Supplementary Table 29).
507 Further, increased risk of pain intensity positively predicted smoking initiation and cigarettes per day.

508 **Genetically inferred drug repurposing**

509 Of the 156 genes in EAs with evidence supporting causality from fine-mapping and functional
510 genomic prediction, 20 were present in the druggable genome database⁷⁶ (Supplementary Table 30). Of
511 these druggable candidate genes, 11 (including *GRIA1*, *GRK4* and *MST1R*) are tier-1 candidates, which
512 includes targets of licensed drugs and drugs in clinical trial, 4 genes (e.g., *NEK4* and *RYR2*) are in tier 2,
513 and 4 are in tier 3 (Supplementary Table 30). Within tier 1, drugs that interact with *GRK4* (a credible pain
514 gene locus in moderate LD with the novel index variant *NOP14**rs71597204 – Supplementary Figure 12)
515 are beta-blockers (atenolol and metoprolol) and a calcium-channel blocking agent (verapamil) (Figure
516 4B), which have analgesic effects in osteoarthritis^{90,91} and migraine⁹². Another tier-1 candidate gene –
517 *GRIA1* – is targeted by anesthetics (sevoflurane, isoflurane, desflurane), antiepileptics (topiramate,
518 perampanel), analgesics (methoxyflurane), psychoanaleptics (piracetam, aniracetam), and a diuretic
519 (cyclothiazide) (Figure 4B). Drug classes for pain intensity also included anti-hemorrhagic agents (e.g.,
520 fostamatinib [tier 1: *MST1R* and *FYN*; tier 2: *NEK4*] and menadione [*VKORC1*]) (Figure 4B, Supplementary
521 Table 30).

522 Of the 7 genes associated with pain intensity in AAs, *PPARD*, which harbors the new genetic
523 signal discovered in this study, is a tier-1 druggable candidate with 30 interacting drug classes
524 (Supplementary Table 30). The *PPARD* negative modulator sulindac is an approved non-steroidal anti-
525 inflammatory and antirheumatic drug used to treat osteoarthritis.

526

527 **Discussion**

528 We conducted the largest multi-ancestry, single-sample GWAS of pain intensity to date,
529 comprising 112,968 AA, 436,683 EA, and 48,688 HA individuals. Cross-ancestry analyses identified 125
530 independent risk loci, of which 82 have not previously been associated with any pain phenotype.
531 Although prior GWASs for chronic pain phenotypes have identified 99 loci^{23-27,32}, the study samples have
532 largely been limited to EA individuals. The diversity of the MVP sample enabled us to identify novel
533 association signals in both AAs (*PPARD**rs9470000) and HAs (nearest genes *RNU6-461P**rs146862033,
534 *RNU6-741P**rs1019597899).

535 Findings from gene set analysis, tissue enrichment, and cell-type specificity highlight novel
536 biological pathways linking genetic variation to the etiopathology of pain. These functional analyses all
537 implicate the brain, providing genetic support to the current understanding of the pathophysiology of
538 pain severity⁹³. Genes predominantly expressed in the CNS, particularly in the cerebellum, cerebellar
539 hemisphere, and cortex region, rather than in the DRG, appear to play a salient role in modulating the
540 intensity of pain, consistent with prior associations of sustained chronic pain intensity with increased
541 activity in these brain regions⁹⁴⁻⁹⁶. Our findings are also consistent with prior reports^{24,25,97,98} of enriched
542 gene expression in brain that contribute to pain intensity in a dose- and time-dependent manner and
543 may involve specific neuronal processes in brain regions implicated in emotional processing⁹³. Evidence
544 that GABAergic neurons are cells of specific interest is a key novel finding. GABA has long been
545 implicated in the modulation and perception of pain⁹⁹⁻¹⁰¹ and previous work has implicated specific
546 GABAergic activity in the midbrain as a modulator of pain and anxiety¹⁰². Altered GABA levels have been
547 reported in individuals with various types of pain^{103,104}, and have been associated with greater self-
548 reported pain¹⁰⁵. Targeting GABA functioning (e.g.,¹⁰⁶), particularly in the brain regions enriched for pain
549 intensity, may represent a novel therapeutic strategy.

550 Eleven of 156 prioritized genes encode druggable small molecules that are targets of licensed
551 drugs or those in clinical trials, representing drug repurposing opportunities for treating chronic pain.
552 We highlight *GRK4* and *GRIA1*, each with at least three lines of evidence supporting their involvement in
553 chronic pain. *GRK4* encodes G protein-coupled receptor kinase 4 and has been linked with
554 hypertension¹⁰⁷, which is associated with chronic pain at the population level^{108,109}. Of note, *GRK4*
555 showed significant upregulation in the cerebellar hemisphere, fine maps to an intronic variant with >
556 95% PP, and is a target of beta-blockers. The use of beta-blockers has been associated with reduced
557 osteoarthritis pain scores, prescription analgesic use⁹⁰ and consultations for knee osteoarthritis, knee
558 pain, and hip pain⁹¹. *GRIA1* encodes an ionotropic glutamate receptor subunit, an excitatory

559 neurotransmitter receptor at many synapses in the CNS. Loss-of-function mutations in *GRIA1* are linked
560 to neurodevelopmental impairments^{110,111}. The *GRIA1* antagonist sevoflurane reduced pain in patients
561 suffering from chronic venous ulcer¹¹². However, clinical trials of topiramate (another drug target for
562 *GRIA1*) for treating neuropathic chronic pain are inconclusive¹¹³. Research on the mechanisms that
563 underlie the biology of these potential drug targets for *GRK4* and *GRIA1* and their effects on the onset
564 and severity of chronic pain are warranted.

565 Pain intensity was strongly genetically correlated with other chronic pain phenotypes.
566 Corroborating existing epidemiological studies on the comorbid nature of different pain conditions³³, the
567 strongest genetic correlations of pain intensity were with multisite chronic pain, followed by pain in
568 specific bodily locations. In line with previous observations in GWASs of other pain-related
569 phenotypes^{24,25,27,28,89}, there were also positive genetic correlations of pain intensity with psychiatric
570 disorders, substance use and use disorders, and anthropometric traits.

571 PheWAS findings in both the Yale-Penn sample – enriched for individuals with substance-related
572 traits – and the PMBB – comprising a medical population – were prominent in EAs. These findings
573 underscore the important influence of co-occurring substance-related, psychiatric, and medical
574 pathology and educational achievement on the intensity of the pain experience. In contrast, the PRS
575 generated from the pain intensity discovery sample in AAs yielded few associations in either of the
576 target samples, which underscores the need for larger non-European samples to elucidate the genetic
577 architecture of pain intensity.

578 Two-sample MR analysis supported causal associations between pain and multiple traits.
579 Smoking has previously been associated with greater pain intensity, but studies can be confounded by
580 socioeconomic factors, and a bi-directional relationship has been proposed¹¹⁴. Here, we show evidence
581 for a causal relationship of pain on the number of cigarettes smoked per day, smoking initiation, and
582 smoking cessation. In line with previous findings^{25,33,35,36}, pain intensity had a bidirectional causal effect
583 on the risk of both depression and neuroticism, suggesting that greater pain could predispose
584 individuals to increased risk for these psychiatric disorders and vice versa. Supporting the positive
585 genetic correlation between opioid use and pain intensity, MR showed evidence of a bidirectional causal
586 effect between pain intensity and opioid use.

587 Our findings underscore the complex nature of pain intensity, with the hundreds of genetic loci
588 contributing to the experience of pain identified here and in prior studies reflecting a substantial genetic

589 contribution to pain-related traits. The evidence adduced here of pleiotropy of pain intensity with
590 psychiatric traits such as neuroticism and depression reflects the contribution of non-physical factors to
591 the experience of pain intensity. This is consistent with the observed significant tissue-group enrichment
592 in CNS, the predominant gene expression findings in brain (including the hippocampus and limbic
593 system), and the SNP-based enhancer enrichments in histone modification in brain tissues (including the
594 dorsolateral prefrontal cortex, inferior temporal lobe, angular gyrus, and anterior caudate).

595 A limitation of the present study concerns the NRS phenotype. Although such a quantitative trait
596 is more informative than a binary one (e.g., the presence of a specific pain diagnosis), it is based on
597 subjective report. However, because the subjective experience of pain is a key defining feature of the
598 clinical phenomenon^{1,115} the phenotype has high public health significance. Pain scores recorded by
599 clerks and nurses in the clinical setting may consistently under report the patient's response. In earlier
600 work that compared self-reported pain from a direct patient survey to scores recorded in a VA clinical
601 setting¹¹⁷, we found that, despite lower scores recorded in the clinic the two reports correlated well.
602 Nonetheless, the imprecise measurement of pain intensity likely yields lower power for gene discovery.
603 The routine assessment of pain severity provided a very large number of pain scores, which we reduced
604 by taking the median of medians for each individual as a trait for GWAS. In subsequent analyses, we plan
605 to evaluate alternative methods for characterizing pain severity (e.g., pain trajectories). Another
606 limitation is that our sample comprises predominantly male veterans, which in view of well
607 demonstrated sex differences in the experience and frequency of pain²⁶, limits the application of the
608 findings to the general population. Finally, although our sample was more diverse than prior GWAS of
609 pain traits, analyses in the AA and HA samples were underpowered.

610 Despite these limitations, the large MVP sample and informative quantitative trait measured
611 repeatedly within subjects enabled us to generate a proxy for chronic pain and identify many novel loci
612 contributing to the trait. Downstream analyses localize the genetic effects largely to four CNS regions
613 and using available single-cell RNAseq data specifically to GABAergic neurons. Combined with drug
614 repurposing findings that implicate 20 druggable targets, the study provides a basis for studies of novel,
615 non-opioid medications for use in alleviating chronic pain.

616

617

618

619 Figure Legends

620 **Figure 1. Manhattan plot for the pain intensity cross-ancestry GWAS meta-analysis.** This identified 125
621 independent index variants. SNPs above the red line are GWS after correction for multiple testing
622 ($P < 5 \times 10^{-8}$)

623

624 **Figure 2. Enrichment of pain intensity in the brain. A,** Partitioning heritability enrichment analyses using
625 LDSC showing enrichment for pain intensity in the CNS, adrenal, liver, cardiovascular, and skeletal
626 tissues. The dashed black lines indicate Bonferroni-corrected significance ($P < 0.005$). **B,** Proportion of
627 heritability shows robust enrichment for SNPs in brain and immune-related tissues. Heritability
628 enrichment analyses for gene expression (**C & D**) and chromatin interaction (top 35 annotations are
629 shown in **E**, see supplementary Table 12 for full details) using GTEx data show enrichment for pain
630 intensity in brain regions previously associated with chronic pain. Bonferroni correction was applied
631 within each tissue conditioned on the number of genes tested.

632

633 **Figure 3. Gene prioritization for pain intensity. A,** Genomic annotation of credible sets using FINEMAP
634 shows enrichment largely in non-coding regions and to a lesser extent in exons. **B,** Annotation of known
635 and novel credible genes. Dashed lines indicate posterior probability > 0.5. **C,** Number of overlapping
636 genes across functional prediction models. **D,** Tissue enrichment of prioritized genes using SMR and
637 GTEx data show enrichment in brain regions. Size of circle reflects $-\log_{10}P$. Bonferroni correction was
638 applied within each tissue conditioned on the number of genes tested.

639

640 **Figure 4. Genetic correlation and drug repurposing. A,** Genetic correlation for pain intensity using LDSC.
641 All points passing Bonferroni correction (Bonferroni correction threshold = 5.62×10^{-4} [0.05/89]) are
642 plotted. The color of the circle indicates the phenotypic category. **B,** Druggable targets and drug
643 interactions for 8 credible genes associated with pain intensity. For a full list of credible drug targets see
644 Supplementary Table 30.

645

646

647 **Data Availability.** The full summary statistics from the meta-analyses will be available through dbGaP
648 upon publication.

649

650 **Code Availability.** Imputation was performed using Minimac3
651 (<https://genome.sph.umich.edu/wiki/Minimac3>). GWAS was performed using PLINK2 (<https://www.cog->
652 [genomics.org/plink2](https://www.cog-genomics.org/plink2)). Meta-analyses were performed using METAL
653 (https://genome.sph.umich.edu/wiki/METAL_Documentation). GCTA-COJO
654 (<https://cnsgenomics.com/software/gcta/#Overview>) was used for identification of independent loci.
655 FUMA (<https://fuma.ctglab.nl/>) was used for gene association, functional enrichment and gene-set
656 enrichment analyses. Transcriptomic and proteomic analyses were performed using FUSION
657 (https://github.com/gusevlab/fusion_twas). Chromatin accessibility analyses were performed using H-
658 MAGMA (<https://github.com/thewonlab/H-MAGMA>). LDSC (<https://github.com/bulik/ldsc>) was used for
659 heritability estimation, genetic correlation analysis (also using the CTG-VL; <https://genoma.io>) and
660 heritability enrichment analyses. Trans-ancestry genetic correlation was estimated using Popcorn
661 (<https://github.com/brielin/Popcorn>). PRS analyses were performed using PRS-CS
662 (<https://github.com/getian107/PRScs>). PheWAS analyses were run using the PheWAS R package
663 (<https://github.com/PheWAS/PheWAS>). The MendelianRandomization R package (<https://cran.r->
664 [project.org/web/packages/MendelianRandomization/index.html](https://cran.r-project.org/web/packages/MendelianRandomization/index.html)) was used for MR analyses.

665

666 **Acknowledgements.** This work was supported by grants from the US Department of Veterans Affairs
667 Biomedical Laboratory Research and Development Service (no. I01 BX003341 (to A.C.J. and H.R.K.)) and
668 the VISN 4 Mental Illness Research, Education and Clinical Center (to H.R.K.); and NIH grants K01
669 AA028292 (to R.L.K.); and P30 DA046345 (to H.R.K.). The funders had no role in study design, data
670 collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in
671 this article are those of the authors and do not necessarily represent the position or policy of the
672 Department of Veterans Affairs or the US Government.

673 We acknowledge the Penn Medicine BioBank (PMBB) for providing data to generate polygenic risk
674 scores and conduct PheWAS analyses and thank the patients of Penn Medicine who consented to
675 participate in this research program. We would also like to thank the Penn Medicine BioBank team and
676 Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is approved under

677 IRB protocol# 813913 and supported by Perelman School of Medicine at University of Pennsylvania, a
678 gift from the Smilow family, and the National Center for Advancing Translational Sciences of the
679 National Institutes of Health under CTSA award number UL1TR001878.

680 This manuscript has been co-authored by UT-Battelle, LLC under Contract No. DE-AC05-00OR22725 with
681 the U.S. Department of Energy. The United States Government retains and the publisher, by accepting
682 the article for publication, acknowledges that the United States Government retains a non-exclusive,
683 paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript,
684 or allow others to do so, for United States Government purposes. The Department of Energy will provide
685 public access to these results of federally sponsored research in accordance with the DOE Public Access
686 Plan (<http://energy.gov/downloads/doe-public-access-plan>).

687 **Contributions**

688 S.T conducted the main analyses and drafted the manuscript. R.V.S conducted phenotype-related
689 analyses. Z.J and H.X conducted downstream analyses. D.S annotated gene findings. M.P.V and K.S
690 helped conduct analyses. R.V.S, Z.J, H.X, D.S, E.H, M.P.V, K.S, K.X, J.G, D.A.J, C.T.R, M.C, E.S, and S.G.W
691 helped to write the manuscript. A.C.J obtained funding to support the project and helped to write the
692 manuscript. R.L.K supervised the analyses and helped to write the manuscript. H.R.K conceived the
693 project, obtained funding to support it, and helped to supervise the analyses and write the manuscript.
694 All authors reviewed and approved the final version of the manuscript

695 **Ethics declarations**

696 HRK is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion
697 Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the recipient of
698 research funding and medication supplies from Alkermes for an investigator-initiated study; and a
699 member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which
700 was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and
701 Otsuka. HRK and JG are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-
702 guided dosing of opioid agonists," filed January 24, 2018. ES is a full-time employee of Regeneron
703 Pharmaceuticals. The other authors have no disclosures to make.

704

705

706 **References**

- 707 1. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain
708 definition of pain: concepts, challenges, and compromises. *PAIN*. 2020;161(9).
709 https://journals.lww.com/pain/Fulltext/2020/09000/The_revised_International_Association_for_the_6.6.aspx
710 e.6.aspx
- 711 2. Scher C, Meador L, Van Cleave JH, Reid MC. Moving Beyond Pain as the Fifth Vital Sign and Patient
712 Satisfaction Scores to Improve Pain Care in the 21st Century. *Pain Manag Nurs*. 2018;19(2):125-129.
713 doi:10.1016/j.pmn.2017.10.010
- 714 3. Nestler EJ, Waxman SG. Resilience to Stress and Resilience to Pain: Lessons from Molecular
715 Neurobiology and Genetics. *Trends in Molecular Medicine*. 2020;26(10):924-935.
716 doi:10.1016/j.molmed.2020.03.007
- 717 4. Yong RJ, Mullins PM, Bhattacharyya N. Prevalence of chronic pain among adults in the United
718 States. *Pain*. 2022;163(2):e328-e332. doi:10.1097/j.pain.0000000000002291
- 719 5. Tompkins DA, Hobelmann JG, Compton P. Providing chronic pain management in the “Fifth Vital
720 Sign” Era: Historical and treatment perspectives on a modern-day medical dilemma. *Drug and*
721 *Alcohol Dependence*. 2017;173:S11-S21. doi:10.1016/j.drugalcdep.2016.12.002
- 722 6. Gaskin DJ, Richard P. The economic costs of pain in the United States. *J Pain*. 2012;13(8):715-724.
723 doi:10.1016/j.jpain.2012.03.009
- 724 7. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years
725 lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a
726 systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*.
727 2018;392(10159):1789-1858. doi:10.1016/S0140-6736(18)32279-7
- 728 8. Humphreys K, Shover CL, Andrews CM, et al. Responding to the opioid crisis in North America and
729 beyond: recommendations of the Stanford–Lancet Commission. *The Lancet*. 2022;399(10324):555-
730 604. doi:10.1016/S0140-6736(21)02252-2
- 731 9. Friedman JR, Hansen H. Evaluation of Increases in Drug Overdose Mortality Rates in the US by Race
732 and Ethnicity Before and During the COVID-19 Pandemic. *JAMA Psychiatry*. 2022;79(4):379-381.
733 doi:10.1001/jamapsychiatry.2022.0004
- 734 10. Maher DP, Wong CH, Siah KW, Lo AW. Estimates of Probabilities of Successful Development of Pain
735 Medications: An Analysis of Pharmaceutical Clinical Development Programs from 2000 to 2020.
736 *Anesthesiology*. 2022;137(2):243-251. doi:10.1097/ALN.0000000000004265
- 737 11. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. *Clin J Pain*.
738 2008;24(6):469-478. doi:10.1097/AJP.0b013e31816b2f26
- 739 12. Cheatle MD, Savage SR. Informed consent in opioid therapy: a potential obligation and opportunity.
740 *J Pain Symptom Manage*. 2012;44(1):105-116. doi:10.1016/j.jpainsymman.2011.06.015

- 741 13. Els C, Jackson TD, Kunyk D, et al. Adverse events associated with medium- and long-term use of
742 opioids for chronic non-cancer pain: an overview of Cochrane Reviews. *Cochrane Database Syst Rev.*
743 2017;10(10):CD012509. doi:10.1002/14651858.CD012509.pub2
- 744 14. McDonagh M, Selph S, Buckley D. *Nonopioid Pharmacologic Treatments for Chronic Pain*. Rockville
745 (MD): Agency for Healthcare Research and Quality (US); 2020. Available from:
746 <https://www.ncbi.nlm.nih.gov/books/NBK556277/>
- 747 15. Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved drug
748 indications. *Nature Genetics*. 2015;47(8):856-860. doi:10.1038/ng.3314
- 749 16. King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved?
750 Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug
751 approval. *PLoS Genet*. 2019;15(12):e1008489. doi:10.1371/journal.pgen.1008489
- 752 17. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations.
753 *Nature Reviews Drug Discovery*. 2019;18(1):41-58. doi:10.1038/nrd.2018.168
- 754 18. Nielsen C, Knudsen G, Steingrimsdóttir Ó. Twin studies of pain. *Clinical Genetics*. 2012;82(4):331-
755 340. doi:10.1111/j.1399-0004.2012.01938.x
- 756 19. Sexton JE, Cox JJ, Zhao J, Wood JN. The Genetics of Pain: Implications for Therapeutics. *Annu Rev*
757 *Pharmacol Toxicol*. 2018;58(1):123-142. doi:10.1146/annurev-pharmtox-010617-052554
- 758 20. Abboud C, Duveau A, Bouali-Benazzouz R, et al. Animal models of pain: Diversity and benefits.
759 *Journal of Neuroscience Methods*. 2021;348:108997. doi:10.1016/j.jneumeth.2020.108997
- 760 21. Meng W, Adams MJ, Palmer CNA, et al. Genome-wide association study of knee pain identifies
761 associations with GDF5 and COL27A1 in UK Biobank. *Communications Biology*. 2019;2(1):321.
762 doi:10.1038/s42003-019-0568-2
- 763 22. Meng W, Chan BW, Harris C, et al. A genome-wide association study finds genetic variants
764 associated with neck or shoulder pain in UK Biobank. *Human Molecular Genetics*. 2020;29(8):1396-
765 1404. doi:10.1093/hmg/ddaa058
- 766 23. Suri P, Palmer MR, Tsepilov YA, et al. Genome-wide meta-analysis of 158,000 individuals of
767 European ancestry identifies three loci associated with chronic back pain. *PLoS Genet*.
768 2018;14(9):e1007601. doi:10.1371/journal.pgen.1007601
- 769 24. Freidin MB, Tsepilov YA, Palmer M, et al. Insight into the genetic architecture of back pain and its
770 risk factors from a study of 509,000 individuals. *Pain*. 2019;160(6):1361-1373.
771 doi:10.1097/j.pain.0000000000001514
- 772 25. Johnston KJA, Adams MJ, Nicholl BI, et al. Genome-wide association study of multisite chronic pain
773 in UK Biobank. *PLoS Genetics*. 2019;15(6):e1008164. doi:10.1371/journal.pgen.1008164
- 774 26. Johnston KJA, Ward J, Ray PR, et al. Sex-stratified genome-wide association study of multisite
775 chronic pain in UK Biobank. *PLoS Genet*. 2021;17(4):e1009428. doi:10.1371/journal.pgen.1009428

- 776 27. Mocci E, Ward K, Dorsey SG, Ament SA. GWAS meta-analysis reveals dual neuronal and
777 immunological etiology for pain susceptibility. *medRxiv*. Published online January 1,
778 2021:2021.08.23.21262510. doi:10.1101/2021.08.23.21262510
- 779 28. Rahman MS, Winsvold BS, Chavez Chavez SO, et al. Genome-wide association study identifies
780 RNF123 locus as associated with chronic widespread musculoskeletal pain. *Ann Rheum Dis*.
781 2021;80(9):1227-1235. doi:10.1136/annrheumdis-2020-219624
- 782 29. Meng W, Adams MJ, Hebert HL, Deary IJ, McIntosh AM, Smith BH. A Genome-Wide Association
783 Study Finds Genetic Associations with Broadly-Defined Headache in UK Biobank (N=223,773).
784 *EBioMedicine*. 2018;28:180-186. doi:10.1016/j.ebiom.2018.01.023
- 785 30. Tachmazidou I, Hatzikotoulas K, Southam L, et al. Identification of new therapeutic targets for
786 osteoarthritis through genome-wide analyses of UK Biobank data. *Nature Genetics*. 2019;51(2):230-
787 236. doi:10.1038/s41588-018-0327-1
- 788 31. Boer CG, Hatzikotoulas K, Southam L, et al. Deciphering osteoarthritis genetics across 826,690
789 individuals from 9 populations. *Cell*. 2021;184(18):4784-4818.e17. doi:10.1016/j.cell.2021.07.038
- 790 32. Zorina-Lichtenwalter K, Parisien M, Diatchenko L. Genetic studies of human neuropathic pain
791 conditions: a review. *Pain*. 2018;159(3):583-594. doi:10.1097/j.pain.0000000000001099
- 792 33. Meng W, Adams MJ, Reel P, et al. Genetic correlations between pain phenotypes and depression
793 and neuroticism. *European Journal of Human Genetics*. 2020;28(3):358-366. doi:10.1038/s41431-
794 019-0530-2
- 795 34. Zorina-Lichtenwalter K, Bango CI, Van Oudenhove L, et al. Identification and characterization of
796 genetic risk shared across 24 chronic pain conditions in the UK Biobank. *medRxiv*. Published online
797 January 1, 2022:2022.06.28.22277025. doi:10.1101/2022.06.28.22277025
- 798 35. Tang B, Meng W, Hägg S, Burgess S, Jiang X. Reciprocal interaction between depression and pain:
799 results from a comprehensive bidirectional Mendelian randomization study and functional
800 annotation analysis. *Pain*. 2022;163(1):e40-e48. doi:10.1097/j.pain.0000000000002305
- 801 36. Farrell SF, Kho PF, Lundberg M, et al. A Shared Genetic Signature for Common Chronic Pain
802 Conditions and its Impact on Biopsychosocial Traits. *The Journal of Pain*. Published online October
803 14, 2022. doi:10.1016/j.jpain.2022.10.005
- 804 37. Troiani V, Crist RC, Doyle GA, et al. Genetics and prescription opioid use (GaPO): study design for
805 consenting a cohort from an existing biobank to identify clinical and genetic factors influencing
806 prescription opioid use and abuse. *BMC Med Genomics*. 2021;14(1):253. doi:10.1186/s12920-021-
807 01100-z
- 808 38. Gaziano JM, Concato J, Brophy M, et al. Million Veteran Program: A mega-biobank to study genetic
809 influences on health and disease. *Journal of Clinical Epidemiology*. 2016;70:214-223.
810 doi:10.1016/j.jclinepi.2015.09.016
- 811 39. Luther SL, Finch DK, Bouayad L, et al. Measuring pain care quality in the Veterans Health
812 Administration primary care setting. *PAIN*. 2022;163(6).

- 813 https://journals.lww.com/pain/Fulltext/2022/06000/Measuring_pain_care_quality_in_the_Veteran
814 [s_Health.5.aspx](https://journals.lww.com/pain/Fulltext/2022/06000/Measuring_pain_care_quality_in_the_Veteran)
- 815 40. Farrar JT. A consideration of differences in pain scales used in clinical trials. *PAIN*. 2022;163(12).
816 https://journals.lww.com/pain/Fulltext/2022/12000/A_consideration_of_differences_in_pain_scale
817 [s_used.1.aspx](https://journals.lww.com/pain/Fulltext/2022/12000/A_consideration_of_differences_in_pain_scale)
- 818 41. Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain intensity rating scales. *Pain*.
819 2011;152(10):2399-2404. doi:10.1016/j.pain.2011.07.005
- 820 42. Euasobhon P, Atisook R, Bumrungchatudom K, Zinboonyahgoon N, Saisavoey N, Jensen MP.
821 Reliability and responsivity of pain intensity scales in individuals with chronic pain. *PAIN*.
822 2022;163(12).
823 https://journals.lww.com/pain/Fulltext/2022/12000/Reliability_and_responsivity_of_pain_intensity
824 [.6.aspx](https://journals.lww.com/pain/Fulltext/2022/12000/Reliability_and_responsivity_of_pain_intensity)
- 825 43. Edlund MJ, Austen MA, Sullivan MD, et al. Patterns of opioid use for chronic noncancer pain in the
826 Veterans Health Administration from 2009 to 2011. *Pain*. 2014;155(11):2337-2343.
827 doi:10.1016/j.pain.2014.08.033
- 828 44. Department of Veterans Affairs. Pain Management - VHA Directive 2009-053. Published online
829 October 28, 2009. <https://www.va.gov/painmanagement/docs/vha09paindirective.pdf>
- 830 45. Hunter-Zinck H, Shi Y, Li M, et al. Genotyping Array Design and Data Quality Control in the Million
831 Veteran Program. *The American Journal of Human Genetics*. 2020;106(4):535-548.
832 doi:10.1016/j.ajhg.2020.03.004
- 833 46. Delaneau O, Zagury JF, Robinson MR, Marchini JL, Dermitzakis ET. Accurate, scalable and integrative
834 haplotype estimation. *Nature Communications*. 2019;10(1):5436. doi:10.1038/s41467-019-13225-y
- 835 47. Das S, Forer L, Schönherr S, et al. Next-generation genotype imputation service and methods.
836 *Nature Genetics*. 2016;48(10):1284-1287. doi:10.1038/ng.3656
- 837 48. Auton A, Abecasis GR, Altshuler DM, et al. A global reference for human genetic variation. *Nature*.
838 2015;526(7571):68-74. doi:10.1038/nature15393
- 839 49. Fang H, Hui Q, Lynch J, et al. Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in
840 Genome-wide Association Studies. *The American Journal of Human Genetics*. 2019;105(4):763-772.
841 doi:10.1016/j.ajhg.2019.08.012
- 842 50. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the
843 challenge of larger and richer datasets. *GigaScience*. 2015;4(1):s13742-015-0047-0048.
844 doi:10.1186/s13742-015-0047-8
- 845 51. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association
846 scans. *Bioinformatics*. 2010;26(17):2190-2191. doi:10.1093/bioinformatics/btq340


- 847 52. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of
848 genetic associations with FUMA. *Nature Communications*. 2017;8(1):1826. doi:10.1038/s41467-017-
849 01261-5
- 850 53. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. *Am*
851 *J Hum Genet*. 2011;88(1):76-82. doi:10.1016/j.ajhg.2010.11.011
- 852 54. Benner C, Spencer CCA, Havulinna AS, Salomaa V, Ripatti S, Pirinen M. FINEMAP: efficient variable
853 selection using summary data from genome-wide association studies. *Bioinformatics*.
854 2016;32(10):1493-1501. doi:10.1093/bioinformatics/btw018
- 855 55. Benner C, Havulinna AS, Järvelin MR, Salomaa V, Ripatti S, Pirinen M. Prospects of Fine-Mapping
856 Trait-Associated Genomic Regions by Using Summary Statistics from Genome-wide Association
857 Studies. *The American Journal of Human Genetics*. 2017;101(4):539-551.
858 doi:10.1016/j.ajhg.2017.08.012
- 859 56. Bulik-Sullivan BK, Loh PR, Finucane HK, et al. LD Score regression distinguishes confounding from
860 polygenicity in genome-wide association studies. *Nature Genetics*. 2015;47(3):291-295.
861 doi:10.1038/ng.3211
- 862 57. Altshuler DM, Gibbs RA, Peltonen L, et al. Integrating common and rare genetic variation in diverse
863 human populations. *Nature*. 2010;467(7311):52-58. doi:10.1038/nature09298
- 864 58. Luo Y, Li X, Wang X, et al. Estimating heritability and its enrichment in tissue-specific gene sets in
865 admixed populations. *Human Molecular Genetics*. 2021;30(16):1521-1534.
866 doi:10.1093/hmg/ddab130
- 867 59. Finucane HK, Bulik-Sullivan B, Gusev A, et al. Partitioning heritability by functional annotation using
868 genome-wide association summary statistics. *Nature Genetics*. 2015;47(11):1228-1235.
869 doi:10.1038/ng.3404
- 870 60. Finucane HK, Reshef YA, Anttila V, et al. Heritability enrichment of specifically expressed genes
871 identifies disease-relevant tissues and cell types. *Nature Genetics*. 2018;50(4):621-629.
872 doi:10.1038/s41588-018-0081-4
- 873 61. The GTEx consortium, Aguet François, Anand Shankara, et al. The GTEx Consortium atlas of genetic
874 regulatory effects across human tissues. *Science*. 2020;369(6509):1318-1330.
875 doi:10.1126/science.aaz1776
- 876 62. Bernstein BE, Stamatoyannopoulos JA, Costello JF, et al. The NIH Roadmap Epigenomics Mapping
877 Consortium. *Nat Biotechnol*. 2010;28(10):1045-1048. doi:10.1038/nbt1010-1045
- 878 63. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of GWAS
879 Data. *PLOS Computational Biology*. 2015;11(4):e1004219. doi:10.1371/journal.pcbi.1004219
- 880 64. Sey NYA, Hu B, Mah W, et al. A computational tool (H-MAGMA) for improved prediction of brain-
881 disorder risk genes by incorporating brain chromatin interaction profiles. *Nature Neuroscience*.
882 2020;23(4):583-593. doi:10.1038/s41593-020-0603-0






- 883 65. Rajarajan P, Borrman T, Liao W, et al. Neuron-specific signatures in the chromosomal connectome
884 associated with schizophrenia risk. *Science*. 2018;362(6420). doi:10.1126/science.aat4311
- 885 66. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures
886 Database (MSigDB) hallmark gene set collection. *Cell Syst*. 2015;1(6):417-425.
887 doi:10.1016/j.cels.2015.12.004
- 888 67. Watanabe K, Umičević Mirkov M, de Leeuw CA, van den Heuvel MP, Posthuma D. Genetic mapping
889 of cell type specificity for complex traits. *Nature Communications*. 2019;10(1):3222.
890 doi:10.1038/s41467-019-11181-1
- 891 68. Wingo AP, Liu Y, Gerasimov ES, et al. Integrating human brain proteomes with genome-wide
892 association data implicates new proteins in Alzheimer's disease pathogenesis. *Nature Genetics*.
893 2021;53(2):143-146. doi:10.1038/s41588-020-00773-z
- 894 69. Fromer M, Roussos P, Sieberts SK, et al. Gene expression elucidates functional impact of polygenic
895 risk for schizophrenia. *Nature Neuroscience*. 2016;19(11):1442-1453. doi:10.1038/nn.4399
- 896 70. Wingo TS, Liu Y, Gerasimov ES, et al. Shared mechanisms across the major psychiatric and
897 neurodegenerative diseases. *Nature Communications*. 2022;13(1):4314. doi:10.1038/s41467-022-
898 31873-5
- 899 71. Gusev A, Ko A, Shi H, et al. Integrative approaches for large-scale transcriptome-wide association
900 studies. *Nature Genetics*. 2016;48(3):245-252. doi:10.1038/ng.3506
- 901 72. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian Test for Colocalisation between Pairs of
902 Genetic Association Studies Using Summary Statistics. *PLOS Genetics*. 2014;10(5):e1004383.
903 doi:10.1371/journal.pgen.1004383
- 904 73. Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL studies predicts
905 complex trait gene targets. *Nature Genetics*. 2016;48(5):481-487. doi:10.1038/ng.3538
- 906 74. Qi T, Wu Y, Fang H, et al. Genetic control of RNA splicing and its distinct role in complex trait
907 variation. *Nature Genetics*. 2022;54(9):1355-1363. doi:10.1038/s41588-022-01154-4
- 908 75. Ray P, Torck A, Quigley L, et al. Comparative transcriptome profiling of the human and mouse dorsal
909 root ganglia: an RNA-seq-based resource for pain and sensory neuroscience research. *PAIN*.
910 2018;159(7).
911 [https://journals.lww.com/pain/Fulltext/2018/07000/Comparative_transcriptome_profiling_of_the_](https://journals.lww.com/pain/Fulltext/2018/07000/Comparative_transcriptome_profiling_of_the_human.16.aspx)
912 [human.16.aspx](https://journals.lww.com/pain/Fulltext/2018/07000/Comparative_transcriptome_profiling_of_the_human.16.aspx)
- 913 76. Finan C, Gaulton A, Kruger FA, et al. The druggable genome and support for target identification and
914 validation in drug development. *Sci Transl Med*. 2017;9(383). doi:10.1126/scitranslmed.aag1166
- 915 77. Gaulton A, Bellis LJ, Bento AP, et al. ChEMBL: a large-scale bioactivity database for drug discovery.
916 *Nucleic Acids Res*. 2012;40(Database issue):D1100-1107. doi:10.1093/nar/gkr777
- 917 78. Cotto KC, Wagner AH, Feng YY, et al. DGIdb 3.0: a redesign and expansion of the drug-gene
918 interaction database. *Nucleic Acids Research*. 2018;46(D1):D1068-D1073. doi:10.1093/nar/gkx1143





- 919 79. Cuéllar-Partida G, Lundberg M, Kho PF, et al. Complex-Traits Genetics Virtual Lab: A community-
920 driven web platform for post-GWAS analyses. *bioRxiv*. Published online January 1, 2019:518027.
921 doi:10.1101/518027
- 922 80. Brown BC, Ye CJ, Price AL, Zaitlen N. Transethnic Genetic-Correlation Estimates from Summary
923 Statistics. *The American Journal of Human Genetics*. 2016;99(1):76-88.
924 doi:10.1016/j.ajhg.2016.05.001
- 925 81. Kember RL, Hartwell EE, Xu H, et al. Phenome-wide Association Analysis of Substance Use Disorders
926 in a Deeply Phenotyped Sample. *Biological Psychiatry*. doi:10.1016/j.biopsych.2022.08.010
- 927 82. Pierucci-Lagha A, Gelernter J, Feinn R, et al. Diagnostic reliability of the Semi-structured Assessment
928 for Drug Dependence and Alcoholism (SSADDA). *Drug Alcohol Depend*. 2005;80(3):303-312.
929 doi:10.1016/j.drugalcdep.2005.04.005
- 930 83. Pierucci-Lagha A, Gelernter J, Chan G, et al. Reliability of DSM-IV diagnostic criteria using the semi-
931 structured assessment for drug dependence and alcoholism (SSADDA). *Drug Alcohol Depend*.
932 2007;91(1):85-90. doi:10.1016/j.drugalcdep.2007.04.014
- 933 84. Fuchsberger C, Abecasis GR, Hinds DA. minimac2: faster genotype imputation. *Bioinformatics*.
934 2015;31(5):782-784. doi:10.1093/bioinformatics/btu704
- 935 85. Verma A, Damrauer SM, Naseer N, et al. The Penn Medicine BioBank: Towards a Genomics-Enabled
936 Learning Healthcare System to Accelerate Precision Medicine in a Diverse Population. *Journal of*
937 *Personalized Medicine*. 2022;12(12). doi:10.3390/jpm12121974
- 938 86. Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via Bayesian regression and
939 continuous shrinkage priors. *Nature Communications*. 2019;10(1):1776. doi:10.1038/s41467-019-
940 09718-5
- 941 87. Denny JC, Ritchie MD, Basford MA, et al. PheWAS: demonstrating the feasibility of a phenome-wide
942 scan to discover gene–disease associations. *Bioinformatics*. 2010;26(9):1205-1210.
943 doi:10.1093/bioinformatics/btq126
- 944 88. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference
945 across the human phenome. *Elife*. 2018;7. doi:10.7554/eLife.34408
- 946 89. Tsepilov YA, Freidin MB, Shadrina AS, et al. Analysis of genetically independent phenotypes
947 identifies shared genetic factors associated with chronic musculoskeletal pain conditions. *Commun*
948 *Biol*. 2020;3(1):329. doi:10.1038/s42003-020-1051-9
- 949 90. Valdes AM, Abhishek A, Muir K, Zhang W, Maciewicz RA, Doherty M. Association of Beta-Blocker
950 Use With Less Prevalent Joint Pain and Lower Opioid Requirement in People With Osteoarthritis.
951 *Arthritis Care Res (Hoboken)*. 2017;69(7):1076-1081. doi:10.1002/acr.23091
- 952 91. Nakafero G, Grainge MJ, Valdes AM, et al. β -blocker prescription is associated with lower
953 cumulative risk of knee osteoarthritis and knee pain consultations in primary care: a propensity
954 score-matched cohort study. *Rheumatology (Oxford)*. 2021;60(12):5686-5696.
955 doi:10.1093/rheumatology/keab234


- 956 92. Jackson JL, Cogbill E, Santana-Davila R, et al. A Comparative Effectiveness Meta-Analysis of Drugs for
957 the Prophylaxis of Migraine Headache. *PLOS ONE*. 2015;10(7):e0130733.
958 doi:10.1371/journal.pone.0130733
- 959 93. Diatchenko L, Parisien M, Jahangiri Esfahani S, Mogil JS. Omics approaches to discover
960 pathophysiological pathways contributing to human pain. *PAIN*. 2022;163(S1).
961 [https://journals.lww.com/pain/Fulltext/2022/11001/Omics_approaches_to_discover_pathophysiol](https://journals.lww.com/pain/Fulltext/2022/11001/Omics_approaches_to_discover_pathophysiological.7.aspx)
962 [ogical.7.aspx](https://journals.lww.com/pain/Fulltext/2022/11001/Omics_approaches_to_discover_pathophysiological.7.aspx)
- 963 94. Mayr A, Jahn P, Stankewitz A, et al. Patients with chronic pain exhibit individually unique cortical
964 signatures of pain encoding. *Human Brain Mapping*. 2022;43(5):1676-1693. doi:10.1002/hbm.25750
- 965 95. Lee JJ, Lee S, Lee DH, Woo CW. Functional brain reconfiguration during sustained pain. Ploner M,
966 Behrens TE, Ploner M, Spisak T, eds. *eLife*. 2022;11:e74463. doi:10.7554/eLife.74463
- 967 96. Baliki MN, Chialvo DR, Geha PY, et al. Chronic Pain and the Emotional Brain: Specific Brain Activity
968 Associated with Spontaneous Fluctuations of Intensity of Chronic Back Pain. *J Neurosci*.
969 2006;26(47):12165. doi:10.1523/JNEUROSCI.3576-06.2006
- 970 97. Bortsov AV, Parisien M, Khoury S, et al. Brain-specific genes contribute to chronic but not to acute
971 back pain. *PAIN Reports*. 2022;7(5).
972 [https://journals.lww.com/painrpts/Fulltext/2022/10000/Brain_specific_genes_contribute_to_chron](https://journals.lww.com/painrpts/Fulltext/2022/10000/Brain_specific_genes_contribute_to_chronic_but_not.6.aspx)
973 [ic_but_not.6.aspx](https://journals.lww.com/painrpts/Fulltext/2022/10000/Brain_specific_genes_contribute_to_chronic_but_not.6.aspx)
- 974 98. Khoury S, Parisien M, Thompson SJ, et al. Genome-wide analysis identifies impaired axonogenesis in
975 chronic overlapping pain conditions. *Brain*. 2022;145(3):1111-1123. doi:10.1093/brain/awab359
- 976 99. Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. *Adv Pharmacol*.
977 2006;54:1-27. doi:10.1016/s1054-3589(06)54001-3
- 978 100. Goudet C, Magnaghi V, Landry M, Nagy F, Gereau RW 4th, Pin JP. Metabotropic receptors for
979 glutamate and GABA in pain. *Brain Res Rev*. 2009;60(1):43-56.
980 doi:10.1016/j.brainresrev.2008.12.007
- 981 101. Dong W, Jin SC, Allocco A, et al. Exome Sequencing Implicates Impaired GABA Signaling and
982 Neuronal Ion Transport in Trigeminal Neuralgia. *iScience*. 2020;23(10):101552.
983 doi:10.1016/j.isci.2020.101552
- 984 102. Xie L, Wu H, Chen Q, et al. Divergent modulation of pain and anxiety by GABAergic neurons in
985 the ventrolateral periaqueductal gray and dorsal raphe. *Neuropsychopharmacology*. Published
986 online December 16, 2022. doi:10.1038/s41386-022-01520-0
- 987 103. Bridge H, Stagg CJ, Near J, Lau C ieong, Zisner A, Cader MZ. Altered neurochemical coupling in
988 the occipital cortex in migraine with visual aura. *Cephalalgia*. 2015;35(11):1025-1030.
989 doi:10.1177/0333102414566860
- 990 104. Foerster BR, Petrou M, Edden RAE, et al. Reduced insular γ -aminobutyric acid in fibromyalgia.
991 *Arthritis Rheum*. 2012;64(2):579-583. doi:10.1002/art.33339

- 992 105. Wu X, Yuan J, Yang Y, et al. Elevated GABA level in the precuneus and its association with pain
993 intensity in patients with postherpetic neuralgia: An initial proton magnetic resonance
994 spectroscopy study. *Eur J Radiol.* 2022;157:110568. doi:10.1016/j.ejrad.2022.110568
- 995 106. Naik AK, Pathirathna S, Jevtovic-Todorovic V. GABAA receptor modulation in dorsal root ganglia
996 in vivo affects chronic pain after nerve injury. *Neuroscience.* 2008;154(4):1539-1553.
997 doi:10.1016/j.neuroscience.2008.04.061
- 998 107. Yang J, Hall JE, Jose PA, Chen K, Zeng C. Comprehensive insights in GRK4 and hypertension: From
999 mechanisms to potential therapeutics. *Pharmacology & Therapeutics.* 2022;239:108194.
1000 doi:10.1016/j.pharmthera.2022.108194
- 1001 108. Olsen RB, Bruehl S, Nielsen CS, Rosseland LA, Eggen AE, Stubhaug A. Hypertension prevalence
1002 and diminished blood pressure-related hypoalgesia in individuals reporting chronic pain in a general
1003 population: The Tromsø Study. *PAIN.* 2013;154(2).
1004 https://journals.lww.com/pain/Fulltext/2013/02000/Hypertension_prevalence_and_diminished_blood.15.aspx
1005
- 1006 109. Li CY, Lin WC, Lu CY, Chung YS, Cheng YC. Prevalence of pain in community-dwelling older adults
1007 with hypertension in the United States. *Scientific Reports.* 2022;12(1):8387. doi:10.1038/s41598-
1008 022-12331-0
- 1009 110. Geisheker MR, Heymann G, Wang T, et al. Hotspots of missense mutation identify
1010 neurodevelopmental disorder genes and functional domains. *Nature Neuroscience.*
1011 2017;20(8):1043-1051. doi:10.1038/nn.4589
- 1012 111. Ismail V, Zachariassen LG, Godwin A, et al. Identification and functional evaluation of GRIA1
1013 missense and truncation variants in individuals with ID: An emerging neurodevelopmental
1014 syndrome. *The American Journal of Human Genetics.* 2022;109(7):1217-1241.
1015 doi:10.1016/j.ajhg.2022.05.009
- 1016 112. Aranke M, Pham CT, Yilmaz M, et al. Topical Sevoflurane: A Novel Treatment for Chronic Pain
1017 Caused by Venous Stasis Ulcers. *Anesth Pain Med.* 2021;11(1):e112832. doi:10.5812/aapm.112832
- 1018 113. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a
1019 systematic review and meta-analysis. *The Lancet Neurology.* 2015;14(2):162-173.
1020 doi:10.1016/S1474-4422(14)70251-0
- 1021 114. Khan JS, Hah JM, Mackey SC. Effects of smoking on patients with chronic pain: a propensity-
1022 weighted analysis on the Collaborative Health Outcomes Information Registry. *PAIN.* 2019;160(10).
1023 https://journals.lww.com/pain/Fulltext/2019/10000/Effects_of_smoking_on_patients_with_chronic_pain_.22.aspx
1024
- 1025 115. Nicholas M, Vlaeyen JWS, Rief W, et al. The IASP classification of chronic pain for ICD-11: chronic
1026 primary pain. *Pain.* 2019;160(1):28-37. doi:10.1097/j.pain.0000000000001390
- 1027 116. Goulet JL, Brandt C, Crystal S, et al. Agreement between electronic medical record-based and
1028 self-administered pain numeric rating scale: clinical and research implications. *Med Care.*
1029 2013;51(3):245-250. doi:10.1097/MLR.0b013e318277f1ad







A**B**